New drug cocktail aims to keep relapsed myeloma in check after second transplant
NCT ID NCT03030261
First seen Jan 12, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tests a combination of three drugs (elotuzumab, pomalidomide, and dexamethasone) given after a second stem cell transplant for people whose multiple myeloma has returned. The goal is to see if this treatment can keep the cancer from progressing for as long as possible. The study involves 25 participants and focuses on controlling the disease rather than curing it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute (Sarah Cannon)
Denver, Colorado, 80218, United States
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.